Market Overview

Innophos Holdings, Inc. Reports Second-Quarter 2018 Results

Share:

Continued Revenue Growth in FHN Segment Driven by Strength in
Legacy and Acquired Portfolios

Recently Signed Milestone Sourcing Agreements Support Strategic
Value Chain Repositioning and 10% Adjusted Earnings Enhancement by End
of 2019

Negotiated $20 Million To Offset Specific Value Chain Transition
Charges Over Time

Innophos Holdings, Inc. (NASDAQ:IPHS) today announced financial results
for its second quarter ended June 30, 2018.

Strategic Highlights

  • Major milestone completed with recently signed strategic PPA and MGA
    supply agreements with Nutrien
  • Negotiated a $20 million payment from Nutrien to offset near-term
    value chain specific transition charges anticipated to be incurred
    through Q2 2019
  • Income from the payment will mostly benefit 2019 to 2021 earnings
  • Full benefits of the multi-faceted value chain repositioning and
    manufacturing optimization program expected to deliver adjusted
    diluted EPS improvement of 10% by the end of 2019

Q2 Financial Highlights

  • Sales of $207 million were up 15% compared with the prior-year due to
    continued stabilization of the base portfolio, contribution from
    acquisitions and ongoing pricing actions
  • FHN segment sales grew 36%, representing 61% of total Company sales
  • GAAP Net Income of $6 million, or $0.31 per share, reflect $4 million,
    or $0.17 per share of specific value chain transition charges, and $3
    million, or $0.10 per share, for the annual Mexico plant maintenance
    stoppage that was completed earlier in the year than planned to
    prepare operations for the new supply agreements. Given their
    project-based nature, the value chain transition charges were excluded
    from adjusted results
  • Adjusted EBITDA of $31 million was $1 million ahead of the same period
    last year and, when excluding the Mexico maintenance stoppage
    expenses, also improved sequentially.
  • Adjusted diluted EPS of $0.55 was down $0.03, or 5% year-over-year due
    to Mexico maintenance stoppage expenses. Excluding these expenses
    adjusted diluted EPS would have been $0.65, up 14% versus prior year
  • Free Cash Flow was down $26 million from the same quarter last year,
    due to lower reported EBITDA, as well as timing of capital
    expenditures and working capital needs to support the value chain
    repositioning and manufacturing optimization program

Management Comments

"We delivered solid topline growth in the second quarter as we continued
to capitalize on the stability of our legacy business, strength of our
acquired businesses and our proactive pricing actions, which offset
input cost increases," said Kim Ann Mink, Ph.D., Chairman, President and
Chief Executive Officer.

"We made significant strides in advancing our strategic value chain
repositioning and manufacturing optimization program which sets us up
well for 2019 and beyond. This program will meaningfully diversify
Innophos' supply base and deliver an improved sustainable cost
structure, while maintaining our market-leadership position in our
cash-generative phosphate portfolio, which is an important component of
our Vision 2022 strategy," continued Mink.

"We are confident that the strategic value chain program will deliver a
10% improvement to our adjusted diluted EPS by the end of 2019. In the
near term there will be a negative impact to our GAAP earnings as the
anticipated specific value chain transition costs are incurred ahead of
the full benefit accruing from the $20 million payment.

"We continue to position Innophos for sustained organic and inorganic
growth," added Mink. "We have strong momentum behind our enterprise-wide
new product development process called SPARC, are progressing with the
integration of our 2017 acquisitions and are actively pursuing
additional M&A opportunities that will further strengthen our position
in attractive FHN markets.

"Our performance in H1 2018 has been defined by solid financial results
and strong momentum as we advance along our Vision 2022 strategic
roadmap to establish Innophos as a leading specialty ingredients
provider. Looking ahead, we are focused on leveraging this momentum and
continuing to put our transformation in action," concluded Mink.

Q2 2018 Results
Variance $
and Variance % in the following tables may not foot due to rounding

$ Millions except EPS

Quarter 2   2018   2017   Variance $   Variance %
Sales       207           179       28   15%
Net Income       6           11       (5)   (44)%
Adj. Net Income       11           11       ---   (4)%
EBITDA       23           28       (6)   (20)%
Adj. EBITDA       31           30       1   3%
Diluted EPS       0.31           0.57       (0.25)   (45)%
Adj. Diluted EPS       0.55           0.57       (0.03)   (5)%
Cash from Ops       16           30       (14)   (46)%
Free Cash Flow       (3)           23       (26)   (115)%
 
  • Sales grew 15% compared with the prior year due to 12% higher volumes,
    and 3% higher prices
  • GAAP Net Income of $6 million, or diluted EPS of $0.31, were down
    versus the prior year reflecting $4 million of specific value chain
    transition charges and $3 million from the annual Mexico plant
    maintenance stoppage charges
  • Adjusted EBITDA of $31 million was ahead of last year due to
    additional earnings from acquisitions, partly offset by $3 million of
    Mexico plant maintenance charges. Adjusted diluted EPS of $0.55 was
    down due to the $0.10 impact from the annual Mexico maintenance
    stoppage
  • Free Cash outflow was $3 million, down $26 million versus the same
    quarter last year due to lower earnings, as well as higher capex of
    $12 million and greater working capital needs to support the value
    chain repositioning and manufacturing optimization program

Q2 2018 Segment Financials

Q2 Sales     2018 $ Millions     2017 $ Millions     Variance $     Variance %
FHN     126     92     33     36%
IS     67     67     (1)     (1)%
Other     14     20     (5)     (27)%
Total Innophos     207     179     28     15%
                         
Q2 Adj. EBITDA     2018 $ Millions     2017 $ Millions     2018 Margin     2017 Margin
FHN     18     18     15%     20%
IS     11     10     16%     14%
Other     2     2     11%     12%
Total IPHS     31     30     15%     17%

Note: See Adjusted EBITDA reconciliation to EBITDA in the
financial tables that follow

 
  • FHN represented 61% of total Company sales and was up 36%
    year-over-year (price +1%, volume +35%) due to the contribution from
    acquisitions and strength of the legacy portfolio; adjusted EBITDA
    margins were 509 bps below 2017 due to the effects of the Mexico plant
    maintenance stoppage and dilution effect from lower margin acquisitions
  • IS sales were down 1% with selling price increases mostly offsetting
    volume (price +3%, volume down 4%); adjusted EBITDA margins were up
    229 bps versus the prior year quarter due to proactive price increases
  • Other sales were down 27% (price +9%, volume down 36%) due primarily
    to the lower level of co-product sales. Other adjusted EBITDA margins
    were 11%

Year-to-Date Results

Variance $ and Variance % in the following tables may not foot due to
rounding

$ Millions except EPS

YTD Q2   2018   2017   Variance $   Variance %
Sales       412           345       67   19%
Net Income       17           22       (5)   (23)%
Adj. Net Income       23           23       ---   ---
EBITDA       52           54       (2)   (3)%
Adj. EBITDA       63           58       5   10%
Diluted EPS       0.87           1.12       (0.25)   (23)%
Adj. Diluted EPS       1.15           1.16       (0.01)   (1)%
Cash from Ops       12           19       (7)   (38)%
Free Cash Flow       (17)           3       (20)   (612)%
 
  • Sales improved 19% reflecting the benefit of acquisitions and
    proactive pricing programs
  • GAAP Net Income of $17 million was impacted by expenses related to the
    value chain transition and Mexico plant maintenance stoppage
  • Adjusted EBITDA grew 10% due to contributions from acquisitions and
    legacy business price increases that exceeded input cost increases
  • Average working capital was 22% for the first half 2018, down 90 bps
    from the prior year half despite increased working capital needs to
    support the value chain repositioning and manufacturing optimization
    program

YTD Quarter 2 Segment Financials

YTD Q2 Segment Sales   2018 $ Millions   2017 $ Millions   Variance $   Variance %
FHN   252   183   69   38%
IS   130   131   (1)   (1)%
Other   30   31   (1)   (2)%
Total Innophos   412   345   67   19%
                 
YTD Q2 Segment Adj. EBITDA   2018 $ Millions   2017 $ Millions   2018 Margin   2017 Margin
FHN   39   35   16%   19%
IS   22   20   17%   15%
Other   2   3   8%   11%
Total IPHS   63   58   15%   17%

Note: See Adjusted EBITDA reconciliation to EBITDA in the
financial tables that follow

 
  • FHN represented 61% of total Company sales and was up 38%
    year-over-year (price +1%, volume +37%) due to the contribution from
    acquisitions and strength of the legacy portfolio; adjusted EBITDA
    margins were 340 bps below 2017 due to the effects of the Mexico plant
    maintenance stoppage and dilution effects from lower margin
    acquisitions
  • IS sales were down 1% with selling price increases nearly offsetting
    volume (price +3%, volume down 4%); adjusted EBITDA margins were up
    169 bps due to price increases
  • Other sales were down 2% (price +7%, volume down 9%) due primarily to
    lower level of co-product sales. Other adjusted EBITDA margins were 8%

Full Year 2018 Outlook

The Company is reiterating its revenue and adjusted earnings guidance
for full year 2018 with revenue to grow 12% to 14% and adjusted EBITDA
to grow 15% to 17% compared to 2017.

The impact from specific value chain transition charges will lower 2018
GAAP earnings expectations as these transition costs will be incurred
ahead of the $20 million accruing to earnings.

Overall market conditions and the competitive landscape are expected to
be similar in H2 compared with H1 of this year.

During the first half of the year, selling price increases have been
effective in offsetting input cost increases. In response to the
operating environment continuing to show cost inflation, the Company
continues to take further price increase actions.

The Company anticipates the effective tax rate to operate in the 28-30%
range given the geographical mix in earnings.

Free cash flow is expected to modestly decrease versus prior year,
principally to support the strategic value chain repositioning and
manufacturing optimization program.

The Company continues to diligently work through the multi-faceted value
chain repositioning and manufacturing optimization program and expects
full benefits to materialize in H2 2019. The program is estimated to
deliver adjusted diluted EPS improvement of 10% by the end of 2019.

Conference Call

Innophos will host its second quarter 2018 conference call today July
30, 2018 at 9:00 am ET to discuss its earnings results. The call can be
accessed by dialing (877) 604-1612 (U.S.) or (201) 389-0883
(international). No passcode is required. Please dial in approximately
15 minutes ahead of the start time to ensure timely entry to the call.
The Q2 2018 earnings call presentation will be made available on the
Company's website the morning of the call. A replay will be available
between approximately 11:30 am ET on July 30 and 11:59 pm ET on August
13, 2018. The replay is accessible by dialing (877) 660-6853 (U.S.) or
(201) 612-7415 (international) and entering the Conference ID number
13681096.

Additional information on Innophos' second quarter 2018 results can also
be found on the Company's website.

About the Company

Innophos is a leading international producer of specialty ingredient
solutions that deliver far-reaching, versatile benefits for the food,
health, nutrition and industrial markets. We leverage our expertise in
the science and technology of blending and formulating phosphate,
mineral, enzyme and botanical based ingredients to help our customers
offer products that are tasty, healthy, nutritious and economical.
Headquartered in Cranbury, New Jersey, Innophos has manufacturing
operations across the United States, in Canada, Mexico and China. For
more information, please visit www.innophos.com.
'IPHS-G'

Financial Tables Follow

Safe Harbor for Forward-Looking and Cautionary
Statements

This press release contains or may contain forward-looking statements
within the meaning of Section 27a of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. The Company intends these forward-looking statements to be
covered by the safe harbor provisions for such statements. Statements
made in this press release that relate to our future performance or
future financial results or other future events (which may be identified
by such terms as "expect," "estimate," "anticipate," "assume,"
"believe," "plan," "intend', "may," "will," "should," "outlook,"
"guidance," "target," "opportunity," "potential" or similar terms and
variations or the negative thereof) are forward-looking statements,
including the Company's expectations regarding the business environment
and the Company's overall guidance regarding future performance and
growth. These statements are based on our current beliefs and
expectations and are subject to significant risks and uncertainties.
Actual results may materially differ from the expectations expressed in
or implied by these forward-looking statements. Factors that could cause
the Company's actual results to differ materially include, but are not
limited to: (1) global macroeconomic conditions and trends; (2) the
behavior of financial markets, including fluctuations in foreign
currencies, interest rates and turmoil in capital markets; (3) changes
in regulatory controls regarding tariffs, duties, taxes and income tax
rates; (4) the Company's ability to implement and refine its Vision 2022
strategic roadmap; (5) the Company's ability to successfully identify
and complete acquisitions in line with its Vision 2022 strategic roadmap
and effectively operate and integrate acquired businesses to realize the
anticipated benefits of those acquisitions; (6) the Company's ability to
realize expected cost savings and efficiencies from its performance
improvement and other optimization initiatives; (7) the Company's
ability to effectively compete in its markets, and to successfully
develop new and competitive products that appeal to its customers; (8)
changes in consumer preferences and demand for the Company's products or
a decline in consumer confidence and spending; (9) the Company's ability
to benefit from its investments in assets and human capital and the
ability to complete projects successfully and on budget; (10) economic,
regulatory and political risks associated with the Company's
international operations, most notably Mexico and China; (11) volatility
and increases in the price of raw materials, energy and transportation,
and fluctuations in the quality and availability of raw materials and
process aids; (12) the impact of a disruption in the Company's supply
chain or its relationship with its suppliers; (13) the Company's ability
to comply with, and the costs associated with compliance with, U.S. and
foreign environmental protection laws and (14) the Company's ability to
meet quality and regulatory standards in the various jurisdictions in
which it has operations or conducts business. We caution you to consider
the important risks and other factors as set forth in the
forward-looking statements section and in Item 1A Risk Factors in our
most recent Annual Report on Form 10-K, as amended by subsequent reports
on Forms 10-Q and 8-K. We do not undertake to update the forward-looking
statements to reflect the impact of circumstances or events that may
arise after the date of the forward-looking statements.

Summary Profit & Loss Statement

 

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Condensed Consolidated Statement of Operations (Unaudited)

(Dollars In thousands, except per share amounts or share
amounts)

 
  Three Months Ended June 30,   Six Month Ended June 30,
2018   2017 2018   2017
 
Net sales $ 206,725 $ 179,140 $ 412,165 $ 345,084
Cost of goods sold   170,340     140,064     333,553     269,465  
Gross profit   36,385     39,076     78,612     75,619  
Operating expenses:
Selling, general and administrative 22,503 19,881 45,023 39,203
Research & development expenses   1,338     818     2,749     1,648  
Total operating expenses   23,841     20,699     47,772     40,851  
Operating income 12,544 18,377 30,840 34,768
Interest expense, net 3,198 1,452 6,102 2,805
Foreign exchange loss (gain) 1,136 (78 ) 940 (135 )
Other income   (13 )   (14 )   (28 )   (28 )
Income before income taxes 8,223 17,017 23,826 32,126
Provision for income taxes   1,977     5,794     6,665     9,980  
Net income $ 6,246   $ 11,223   $ 17,161   $ 22,146  
 
Diluted Earnings Per Participating Share $ 0.31 $ 0.57 $ 0.87 $ 1.12
Diluted weighted average participating shares outstanding 19,818,883 19,692,690 19,765,971 19,693,682
Dividends paid per share of common stock $ 0.48 $ 0.48 $ 0.96 $ 0.96
Dividends declared per share of common stock $ 0.48 $ 0.48 $ 0.96 $ 0.96
 

Adjusted Net Income Reconciliation to Net
Income

 
(Dollars in thousands, except EPS)   Three Months Ended June 30,   Six Month Ended June 30,

2018

  2017

2018

  2017
Net Income $ 6,246 $ 11,223 $ 17,161 $ 22,146
 

Pre-tax Adjustments

Foreign exchange loss (gain) 1,136 (78 ) 940 (135 )
Severance/Restructuring expense 304 326 1,284 1,326
M&A related costs 186 - 938 -
Value chain transition   4,493     -     4,493     -  
Total Pre-tax Adjustments 6,119 248 7,655 1,191
 
Income tax effects on Adjustments   1,471     84     1,933     346  
Adjusted Net Income $ 10,894   $ 11,387   $ 22,883   $ 22,991  
 
Adjusted Diluted Earnings Per Participating Share $ 0.55 $ 0.57 $ 1.15 $ 1.16
 

Adjusted EBITDA Reconciliation to Net
Income

 
(Dollars in thousands)   Three Months Ended June 30,   Six Month Ended June 30,
2018   2017 2018   2017
Net Income $ 6,246 $ 11,223 $ 17,161 $ 22,146
Interest expense, net 3,198 1,452 6,102 2,805
Provision for income taxes 1,977 5,794 6,665 9,980
Depreciation & amortization   11,089     9,550     22,453     19,131  
EBITDA 22,510 28,019 52,381 54,062
 

Adjustments

Non-cash stock compensation 1,993 1,568 2,992 2,285
Foreign exchange loss (gain) 1,136 (78 ) 940 (135 )
Severance/Restructuring expense 304 326 1,284 1,326
M&A related costs 186 - 938 -
Value chain transition   4,493     -     4,493     -  
Adjusted EBITDA $ 30,622   $ 29,835   $ 63,028   $ 57,538  
 
Percent of Sales 14.8 % 16.7 % 15.3 % 16.7 %
 

Segment Adjusted EBITDA Reconciliation to
EBITDA

 
(Dollars in thousands)  

Three Months Ended June 30, 2018

   

Three Months Ended June 30, 2017

           
FHN IS Other Total FHN IS Other Total
EBITDA $

14,939

 

$

7,794

 

($223 ) $

22,510

 

$ 17,032 $

8,654

 

$ 2,333 $ 28,019
 
Non-cash stock compensation 1,128 789 76 1,993 887 621 60 1,568
Foreign exchange loss (gain) 96 0 1,040 1,136 (26 ) 0 (52 ) (78 )
Severance/Restructuring exp. 169 114 21 304 130 196 0 326
M&A related costs 172 0 14 186 0 0 0 0
Value chain transition   1,666       2,219       608       4,493     0       0       0       0  
Adjusted EBITDA $ 18,170     $ 10,916     $ 1,536     $ 30,622   $ 18,023     $ 9,471     $ 2,341     $ 29,835  
 

Six Months Ended June 30, 2018

Six Months Ended June 30, 2017

 
FHN IS Other Total FHN IS Other Total
EBITDA $ 33,931 $ 17,886 $ 564 $ 52,381 $ 32,656 $ 18,175 $ 3,231 $ 54,062
 
Non-cash stock compensation 1,703 1,182 107 2,992 1,293 905 87 2,285
Foreign exchange loss (gain) 9 0 931 940 (30 ) 0 (105 ) (135 )
Severance/Restructuring exp.(inc.) 753 485

46

1,284 665 635 26 1,326
M&A related costs 923 0 15 938 0 0 0 0
Value chain transition   1,666       2,219       608       4,493     0       0       0       0  
Adjusted EBITDA $ 38,985     $ 21,772     $ 2,271       63,028   $ 34,584     $ 19,715     $ 3,239     $ 57,538  
 

Segment Reporting

 
  Three Months Ended June 30,   Six Month Ended June 30,
Segment Net Sales 2018   2017 2018   2017
 
Food, Health and Nutrition $ 125,664 $ 92,198 $ 252,027 $ 183,281
Industrial Specialties 66,751 67,368 130,101 131,040
Other   14,310     19,574     30,037     30,763  
Total $ 206,725   $ 179,140   $ 412,165   $ 345,084  
 
Net Sales % change
Food, Health and Nutrition 36.3 % 37.5 %
Industrial Specialties (0.9 )% (0.7 )%
Other   (26.9 )%   (2.4 )%
Total   15.4 %   19.4 %
 
Segment EBITDA
Food, Health and Nutrition $ 14,939 $ 17,032 $ 33,931 $ 32,656
Industrial Specialties 7,794 8,654 17,886 18,175
Other   (223 )   2,333     564     3,231  
Total $ 22,510   $ 28,019   $ 52,381   $ 54,062  
 
Segment EBITDA % of net sales
Food, Health and Nutrition 11.9 % 18.5 % 13.5 % 17.8 %
Industrial Specialties 11.7 % 12.8 % 13.7 % 13.9 %
Other   (1.6 )%   11.9 %   1.9 %   10.5 %
Total   10.9 %   15.6 %   12.7 %   15.7 %
 
Depreciation and amortization expense
Food, Health and Nutrition $ 7,213 $ 5,498 $ 14,535 $ 11,220
Industrial Specialties 3,368 3,486 7,104 6,858
Other   508     566     814     1,053  
Total $ 11,089   $ 9,550   $ 22,453   $ 19,131  
 

Price / Volume

The Company calculates pure selling price dollar variances as the
selling price for the current year to date period minus the selling
price for the prior year to date period, and then multiplies the
resulting selling price difference by the prior year to date period
volume. The current quarter selling price dollar variance is derived
from the current quarter year to date selling price dollar variance less
the previous quarter year to date selling price dollar variance. The
selling price dollar variance is then divided by the prior period sales
dollars to calculate the percentage change. Volume/mix variance is
calculated as the total sales variance minus the selling price variance.
The following table illustrates the percentage changes in net sales by
reportable segments compared with the same period of the prior year,
including the effect of selling price and volume/mix changes upon
revenue:

 

Three Months Ended June 30, 2018

 

Six Months Ended June 30, 2018

 

Reportable Segments

  Price   Volume/Mix     Total   Price   Volume/Mix     Total
Food, Health and Nutrition 1.2 % 35.1 % 36.3 % 0.9 % 36.6 % 37.5 %
Industrial Specialties 3.2 % (4.1 )% (0.9 )% 2.9 % (3.6 )% (0.7 )%
Other 9.2 % (36.1 )% (26.9 )% 7.0 % (9.4 )% (2.4 )%
Total 2.8 % 12.6 % 15.4 % 2.2 % 17.2 % 19.4 %
 

Summary Cash Flow Statement

 
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Dollars in thousands)
 
  Six Month Ended June 30,
2018   2017
Cash flows provided from operating activities
Net income $ 17,161 $ 22,146

Adjustments to reconcile net income to net cash provided from
operating activities:

Depreciation and amortization 22,453 19,131
Amortization of deferred financing charges 215 215
Deferred income tax provision 97 14
Gain on sale of building - (153 )
Share-based compensation 2,992 2,285
Changes in assets and liabilities:
Increase in accounts receivable (8,110 ) (7,797 )
(Increase) decrease in inventories (13,136 ) 1,650
Increase in other current assets (4,481 ) (5,975 )
Decrease in accounts payable (141 ) (6,389 )
Decrease in other current liabilities (718 ) (2,688 )
Changes in other long-term assets and liabilities   (4,224 )   (3,083 )
Net cash provided from operating activities   12,108     19,356  
Cash flows used for investing activities:
Capital expenditures (29,026 ) (16,077 )
Proceeds from sale of building   -     1,028  
Net cash used for investing activities   (29,026 )   (15,049 )
Cash flows provided by (used for) financing activities:
Long-term debt borrowings 61,000 14,000
Long-term debt repayments (41,000 ) (19,000 )
Restricted stock forfeitures (251 ) (738 )
Dividends paid   (18,782 )   (18,722 )
Net cash provided by (used for) financing activities   967     (24,460 )
Effect of foreign exchange rate changes on cash and cash equivalents   (559 )   162  
Net change in cash (16,510 ) (19,991 )
Cash and cash equivalents at beginning of period   28,782     53,487  
Cash and cash equivalents at end of period $ 12,272   $ 33,496  
 

Cash From Operations Reconciliation to
EBITDA

 
(Dollars in thousands)   Three Months Ended June 30,   Six Month Ended June 30,
2018   2017 2018   2017
EBITDA $ 22,510 $ 28,019 $ 52,381 $ 54,062
 
Operating Working Capital 3,714 7,712 (24,986 ) (21,058 )
Taxes paid (9,420 ) (5,940 ) (12,798 ) (11,365 )
Interest paid (3,699 ) (1,380 ) (6,780 ) (2,685 )
All other including non-cash stock compensation and changes in other
long-term assets and liabilities
  3,197     1,624     4,291     402  
Net cash provided from operations $ 16,302   $ 30,035   $ 12,108   $ 19,356  
 
 

Cash From Operations Reconciliation to
Adjusted EBITDA

 
(Dollars in thousands) Three Months Ended June 30, Six Month Ended June 30,
2018 2017 2018 2017
Adjusted EBITDA $ 30,622 $ 29,835 $ 63,028 $ 57,538
 
Operating Working Capital (2,405 ) 7,464 (32,641 ) (22,249 )
Taxes paid (9,420 ) (5,940 ) (12,798 ) (11,365 )
Interest paid (3,699 ) (1,380 ) (6,780 ) (2,685 )
All other including changes in other long-term assets and liabilities   1,204     56     1,299     (1,883 )
Net cash provided from operations $ 16,302   $ 30,035   $ 12,108   $ 19,356  
 
 

Free Cash Flow Reconciliation to Cash
From Operations

 
(Dollars in thousands) Three Months Ended June 30, Six Month Ended June 30,
2018 2017 2018 2017
 
Cash From Operations $ 16,302 $ 30,035 $ 12,108 $ 19,356
Capital Expenditures   (19,627 )   (7,524 )   (29,026 )   (16,077 )
Free Cash Flow   ($3,325 ) $ 22,511     ($16,918 ) $ 3,279  
 

Summary Balance Sheets

 
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets (Unaudited)
(Dollars In thousands)
 
 

June 30,

 

December 31,

2018

2017

ASSETS
Current assets:
Cash and cash equivalents $

12,272

 

$

28,782

 

Accounts receivable, net 108,935 100,820
Inventories 158,908 145,685
Other current assets   29,502     24,969  
Total current assets 309,617 300,256
Property, plant and equipment, net 232,461 219,297
Goodwill 152,767 152,700
Intangibles and other assets, net   106,307     112,916  
Total assets $ 801,152   $ 785,169  
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current portion of capital leases $ 4 $ 4
Accounts payable, trade and other 70,315 70,445
Other current liabilities   42,196     43,084  
Total current liabilities 112,515 113,533
Long-term debt 330,003 310,005
Other long-term liabilities 23,664 28,072
Total stockholders' equity   334,970     333,559  
Total liabilities and stockholders' equity $ 801,152   $ 785,169  
 

Additional Information

Net debt is a supplemental financial measure that is not required by, or
presented in accordance with, US GAAP. The Company believes net debt is
helpful in analyzing leverage and as a performance measure for purposes
of presentation in this release. The Company defines net debt as total
long-term debt (including any current portion) less cash and cash
equivalents.

Free cash flow is a supplemental financial measure that is not required
by, or presented in accordance with, US GAAP. The Company believes free
cash flow is helpful in analyzing the cash flow generating capability of
the business and as a performance measure for purposes of presentation
in this release. The Company defines free cash flow as net cash provided
from operating activities plus cash used for capital expenditures.

EBITDA, adjusted EBITDA, adjusted net income and adjusted diluted EPS
are supplemental financial measures that are not required by, or
presented in accordance with, US GAAP. The Company believes EBITDA and
adjusted EBITDA are helpful in analyzing the cash flow generating
capability of the business and as performance measures for purposes of
presentation in this release.

Net Working Capital is a supplemental financial measure that is not
required by, or presented in accordance with, US GAAP. The Company
believes net working capital is helpful in analyzing the effects on the
cash flow generating capability of the business and as a performance
measure for purposes of presentation in this release. The Company
defines net working capital as total current assets less cash and cash
equivalents less total current liabilities plus current portion of
capital leases.

Operating Working Capital is a supplemental financial measure that is
not required by, or presented in accordance with, US GAAP. The Company
believes operating working capital is helpful in analyzing the effects
on the cash flow generating capability of the business and as a
performance measure for purposes of presentation in this release. The
Company defines operating working capital as net working capital less
taxes less interest.

Innophos is not able to provide a reconciliation of its expectation for
adjusted earnings to 2018 and 2019 GAAP net income given the dynamic
nature of the strategic value chain repositioning program expenses that
may be incurred. In addition, Innophos is not able to provide a
reconciliation of its 2022 expectation for adjusted EBITDA margin to
GAAP net income due to the number of variables in the projected EBITDA
margin for 2022. As a result we are currently unable to quantify
accurately certain amounts that would be required to be included in GAAP
net income for 2018, 2019 or 2022 or the individual adjustments for such
reconciliation. In addition, we believe such reconciliation would imply
a degree of precision that would be confusing or misleading to investors.

View Comments and Join the Discussion!